Funding agencies: This work was supported by the Centre of reference of Huntington's disease (Ministry of Health, France) and by a Contrat d'interface INSERM (ACBL). Additional support was provided through the NeurATRIS (European Advanced Translational Research Infrastructure in Neurosciences) project, the Groupement d'Intérêt Scientifique (GIS)-Institut des Maladies Rares and the” Biomarker program” AP-HP.
Unified Huntington's disease rating scale for advanced patients: Validation and follow-up study
Article first published online: 25 OCT 2013
© 2013 Movement Disorder Society
Volume 28, Issue 12, pages 1717–1723, October 2013
How to Cite
Youssov, K., Dolbeau, G., Maison, P., Boissé, M.-F., de Langavant, L. C., Roos, R. A.C. and Bachoud-Lévi, A.-C. (2013), Unified Huntington's disease rating scale for advanced patients: Validation and follow-up study. Mov. Disord., 28: 1717–1723. doi: 10.1002/mds.25654
Relevant conflicts of interest/financial disclosures: Dr Maison reports support for eusapharma for analysing the RHLF cohort. Dr Roos receives project grants from CHDI and the Gossweiler Foundation. Dr Bachoud-Lévi serves as an expert for the University of Sacramento, and receives institutional support from the Ministry of Health for the management of the Centre of reference for Huntington's disease. She benefits from a “Contrat d'interface” by the INSERM for conducting her research and a contract with CHDI for Registry.
- Issue published online: 25 OCT 2013
- Article first published online: 25 OCT 2013
- Manuscript Accepted: 29 JUL 2013
- Manuscript Revised: 25 JUL 2013
- Manuscript Received: 6 NOV 2012
This article has been cited by:
- You have free access to this content1